Patients with "blinding" headaches known as Idiopathic Intercranial Hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study reports on a phase two trial of a drug called exenatide, a GLP-1 receptor agonist, as a potential treatment for IIH. The IIH Pressure Trial found that for the seven patients who received regular injections of the drug, currently approved for use in Type 2 Diabetes, led to a drop in pressure in the brain during both short (2.5hrs and 24hrs) and long term (12 weeks) measurements. The trial also saw...